Open Access
Open access
Science, volume 324, issue 5928, pages 801-804

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

Makarov Vadim 1, 2
Manina Giulia 2, 3
Mikušová Katarína 2, 4
Möllmann Ute 2, 5
Ryabova Olga 1, 2
SAINT-JOANIS Brigitte 2, 6
Dhar Neeraj 7
Pasca Maria Rosalia 2, 3
Buroni Silvia 2, 3
Lucarelli Anna Paola 2, 3
Milano Anna 2, 3
De Rossi Edda 2, 3
Beláňová Martina 2, 4
Bobovská Adela 2, 4
Dianišková Petronela 2, 4
Korduláková Jana 2, 4
Sala Claudia 2, 7
Fullam Elizabeth 2, 7
Schneider Patricia 2, 7
McKinney John D. 7
Brodin Priscille 8
Christophe Thierry 8
Waddell Simon 2, 9
Butcher Philip 2, 9
ALBRETHSEN Jakob 2, 10
Rosenkrands Ida 2, 10
Brosch Roland 2, 6
Nandi Vrinda 2, 11
Bharath Sowmya 2, 11
Gaonkar Sheshagiri 2, 11
Shandil Radha. K. 2, 11
Balasubramanian Venkataraman 2, 11
Balganesh Tanjore 2, 11
Tyagi Sandeep 12
Grosset Jacques 12
Riccardi Giovanna 2, 3
Cole Stewart T 2, 7
2
 
New Medicines for Tuberculosis (NM4TB) Consortium ().
4
 
Department of Biochemistry, Faculty of Natural Sciences, Comenius University, Mlynska dolina, 84215 Bratislava, Slovakia.
5
 
Department of Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology–Hans Knoell Institute, Beutenbergstrasse 11a, D-07745 Jena, Germany.
6
 
Institut Pasteur, Integrated Mycobacterial Pathogenomics, 25-28, Rue du Docteur Roux, 75724 Paris Cedex 15, France.
8
 
Inserm Avenir Group, Institut Pasteur Korea, 39-1 Hawolgok-dong, Seongbuk-gu, 136-791 Seoul, Korea.
9
 
Division of Cellular and Molecular Medicine, St. George’s Hospital, University of London, Cranmer Terrace, SW17 ORE London, UK.
11
 
AstraZeneca India, Bellary Road Hebbal, Bangalore, India.
Publication typeJournal Article
Publication date2009-05-08
Journal: Science
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor56.9
ISSN00368075, 10959203
Multidisciplinary
Abstract
Ammunition for the TB Wars Tuberculosis is a major human disease of global importance resulting from infection with the air-borne pathogen Mycobacterium tuberculosis, which is becoming increasingly resistant to all available drugs. An antituberculosis benzothiazinone compound kills mycobacterium in infected cells and in mice. Makarov et al. (p. 801) have identified a sulfur atom and nitro residues important for benzothiazinone's activity and used genetic methods and biochemical analysis to identify its target in blocking arabinogalactan biosynthesis during cell-wall synthesis. The compound affects the same pathway as ethambutol, and thus a benzothiazinone drug has the potential to become an important part of treatment of drug-resistant disease and, possibly, replace the less effective ethambutol in the primary treatment of tuberculosis. An isomerase required for cell-wall synthesis is a target for an alternative drug lead for tuberculosis treatment. New drugs are required to counter the tuberculosis (TB) pandemic. Here, we describe the synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of antimycobacterial agents that kill Mycobacterium tuberculosis in vitro, ex vivo, and in mouse models of TB. Using genetics and biochemistry, we identified the enzyme decaprenylphosphoryl-β-d-ribose 2′-epimerase as a major BTZ target. Inhibition of this enzymatic activity abolishes the formation of decaprenylphosphoryl arabinose, a key precursor that is required for the synthesis of the cell-wall arabinans, thus provoking cell lysis and bacterial death. The most advanced compound, BTZ043, is a candidate for inclusion in combination therapies for both drug-sensitive and extensively drug-resistant TB.

Citations by journals

5
10
15
20
25
30
35
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 34, 5.86%
European Journal of Medicinal Chemistry
34 publications, 5.86%
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, 31, 5.34%
Antimicrobial Agents and Chemotherapy
31 publications, 5.34%
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, 25, 4.31%
Journal of Medicinal Chemistry
25 publications, 4.31%
PLoS ONE
PLoS ONE, 13, 2.24%
PLoS ONE
13 publications, 2.24%
Bioorganic and Medicinal Chemistry Letters
Bioorganic and Medicinal Chemistry Letters, 12, 2.07%
Bioorganic and Medicinal Chemistry Letters
12 publications, 2.07%
ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters, 12, 2.07%
ACS Medicinal Chemistry Letters
12 publications, 2.07%
Bioorganic and Medicinal Chemistry
Bioorganic and Medicinal Chemistry, 9, 1.55%
Bioorganic and Medicinal Chemistry
9 publications, 1.55%
ACS Infectious Diseases
ACS Infectious Diseases, 9, 1.55%
ACS Infectious Diseases
9 publications, 1.55%
Drug Discovery Today
Drug Discovery Today, 8, 1.38%
Drug Discovery Today
8 publications, 1.38%
Microbiology spectrum
Microbiology spectrum, 8, 1.38%
Microbiology spectrum
8 publications, 1.38%
Frontiers in Microbiology
Frontiers in Microbiology, 7, 1.21%
Frontiers in Microbiology
7 publications, 1.21%
Scientific Reports
Scientific Reports, 7, 1.21%
Scientific Reports
7 publications, 1.21%
Tuberculosis
Tuberculosis, 7, 1.21%
Tuberculosis
7 publications, 1.21%
Future Medicinal Chemistry
Future Medicinal Chemistry, 6, 1.03%
Future Medicinal Chemistry
6 publications, 1.03%
Journal of the American Chemical Society
Journal of the American Chemical Society, 6, 1.03%
Journal of the American Chemical Society
6 publications, 1.03%
ChemMedChem
ChemMedChem, 6, 1.03%
ChemMedChem
6 publications, 1.03%
ACS Chemical Biology
ACS Chemical Biology, 6, 1.03%
ACS Chemical Biology
6 publications, 1.03%
MedChemComm
MedChemComm, 6, 1.03%
MedChemComm
6 publications, 1.03%
Future Microbiology
Future Microbiology, 5, 0.86%
Future Microbiology
5 publications, 0.86%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 5, 0.86%
International Journal of Molecular Sciences
5 publications, 0.86%
Pharmaceuticals
Pharmaceuticals, 5, 0.86%
Pharmaceuticals
5 publications, 0.86%
Applied Sciences (Switzerland)
Applied Sciences (Switzerland), 5, 0.86%
Applied Sciences (Switzerland)
5 publications, 0.86%
Nature Communications
Nature Communications, 5, 0.86%
Nature Communications
5 publications, 0.86%
Journal of Biomolecular Structure and Dynamics
Journal of Biomolecular Structure and Dynamics, 5, 0.86%
Journal of Biomolecular Structure and Dynamics
5 publications, 0.86%
Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, 5, 0.86%
Biomedicine and Pharmacotherapy
5 publications, 0.86%
Medicinal Research Reviews
Medicinal Research Reviews, 5, 0.86%
Medicinal Research Reviews
5 publications, 0.86%
RSC Medicinal Chemistry
RSC Medicinal Chemistry, 5, 0.86%
RSC Medicinal Chemistry
5 publications, 0.86%
RSC Advances
RSC Advances, 5, 0.86%
RSC Advances
5 publications, 0.86%
Current Topics in Medicinal Chemistry
Current Topics in Medicinal Chemistry, 4, 0.69%
Current Topics in Medicinal Chemistry
4 publications, 0.69%
5
10
15
20
25
30
35

Citations by publishers

20
40
60
80
100
120
140
Elsevier
Elsevier, 133, 22.93%
Elsevier
133 publications, 22.93%
American Chemical Society (ACS)
American Chemical Society (ACS), 71, 12.24%
American Chemical Society (ACS)
71 publications, 12.24%
Springer Nature
Springer Nature, 60, 10.34%
Springer Nature
60 publications, 10.34%
American Society for Microbiology
American Society for Microbiology, 45, 7.76%
American Society for Microbiology
45 publications, 7.76%
Wiley
Wiley, 44, 7.59%
Wiley
44 publications, 7.59%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 29, 5%
Multidisciplinary Digital Publishing Institute (MDPI)
29 publications, 5%
Taylor & Francis
Taylor & Francis, 24, 4.14%
Taylor & Francis
24 publications, 4.14%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 24, 4.14%
Royal Society of Chemistry (RSC)
24 publications, 4.14%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 17, 2.93%
Public Library of Science (PLoS)
17 publications, 2.93%
Oxford University Press
Oxford University Press, 12, 2.07%
Oxford University Press
12 publications, 2.07%
Bentham Science
Bentham Science, 11, 1.9%
Bentham Science
11 publications, 1.9%
Future Medicine
Future Medicine, 11, 1.9%
Future Medicine
11 publications, 1.9%
Frontiers Media S.A.
Frontiers Media S.A., 11, 1.9%
Frontiers Media S.A.
11 publications, 1.9%
American Society for Biochemistry and Molecular Biology
American Society for Biochemistry and Molecular Biology, 5, 0.86%
American Society for Biochemistry and Molecular Biology
5 publications, 0.86%
Wolters Kluwer Health
Wolters Kluwer Health, 4, 0.69%
Wolters Kluwer Health
4 publications, 0.69%
American Association for the Advancement of Science (AAAS)
American Association for the Advancement of Science (AAAS), 4, 0.69%
American Association for the Advancement of Science (AAAS)
4 publications, 0.69%
Proceedings of the National Academy of Sciences (PNAS)
Proceedings of the National Academy of Sciences (PNAS), 4, 0.69%
Proceedings of the National Academy of Sciences (PNAS)
4 publications, 0.69%
International Union of Crystallography (IUCr)
International Union of Crystallography (IUCr), 3, 0.52%
International Union of Crystallography (IUCr)
3 publications, 0.52%
Microbiology Society
Microbiology Society, 3, 0.52%
Microbiology Society
3 publications, 0.52%
The Royal Society
The Royal Society, 3, 0.52%
The Royal Society
3 publications, 0.52%
EMBO press
EMBO press, 3, 0.52%
EMBO press
3 publications, 0.52%
Mary Ann Liebert
Mary Ann Liebert, 2, 0.34%
Mary Ann Liebert
2 publications, 0.34%
SAGE
SAGE, 2, 0.34%
SAGE
2 publications, 0.34%
Tuberculosis Association of India, 2, 0.34%
Tuberculosis Association of India
2 publications, 0.34%
, 2, 0.34%
2 publications, 0.34%
Consilium Medicum, 2, 0.34%
Consilium Medicum
2 publications, 0.34%
The American Association of Immunologists
The American Association of Immunologists, 1, 0.17%
The American Association of Immunologists
1 publication, 0.17%
Editions E D K, 1, 0.17%
Editions E D K
1 publication, 0.17%
NEJM Group
NEJM Group, 1, 0.17%
NEJM Group
1 publication, 0.17%
20
40
60
80
100
120
140
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Makarov V. et al. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis // Science. 2009. Vol. 324. No. 5928. pp. 801-804.
GOST all authors (up to 50) Copy
Makarov V. et al. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis // Science. 2009. Vol. 324. No. 5928. pp. 801-804.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1126/science.1171583
UR - https://doi.org/10.1126%2Fscience.1171583
TI - Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
T2 - Science
AU - Makarov, Vadim
AU - Manina, Giulia
AU - Mikušová, Katarína
AU - Möllmann, Ute
AU - Ryabova, Olga
AU - SAINT-JOANIS, Brigitte
AU - Dhar, Neeraj
AU - Pasca, Maria Rosalia
AU - Buroni, Silvia
AU - Lucarelli, Anna Paola
AU - Milano, Anna
AU - De Rossi, Edda
AU - Beláňová, Martina
AU - Bobovská, Adela
AU - Dianišková, Petronela
AU - Korduláková, Jana
AU - Sala, Claudia
AU - Fullam, Elizabeth
AU - Schneider, Patricia
AU - McKinney, John D.
AU - Brodin, Priscille
AU - Christophe, Thierry
AU - Waddell, Simon
AU - Butcher, Philip
AU - ALBRETHSEN, Jakob
AU - Rosenkrands, Ida
AU - Brosch, Roland
AU - Nandi, Vrinda
AU - Bharath, Sowmya
AU - Gaonkar, Sheshagiri
AU - Shandil, Radha. K.
AU - Balasubramanian, Venkataraman
AU - Balganesh, Tanjore
AU - Tyagi, Sandeep
AU - Grosset, Jacques
AU - Riccardi, Giovanna
AU - Cole, Stewart T
PY - 2009
DA - 2009/05/08 00:00:00
PB - American Association for the Advancement of Science (AAAS)
SP - 801-804
IS - 5928
VL - 324
PMID - 19299584
SN - 0036-8075
SN - 1095-9203
ER -
BibTex |
Cite this
BibTex Copy
@article{2009_Makarov,
author = {Vadim Makarov and Giulia Manina and Katarína Mikušová and Ute Möllmann and Olga Ryabova and Brigitte SAINT-JOANIS and Neeraj Dhar and Maria Rosalia Pasca and Silvia Buroni and Anna Paola Lucarelli and Anna Milano and Edda De Rossi and Martina Beláňová and Adela Bobovská and Petronela Dianišková and Jana Korduláková and Claudia Sala and Elizabeth Fullam and Patricia Schneider and John D. McKinney and Priscille Brodin and Thierry Christophe and Simon Waddell and Philip Butcher and Jakob ALBRETHSEN and Ida Rosenkrands and Roland Brosch and Vrinda Nandi and Sowmya Bharath and Sheshagiri Gaonkar and Radha. K. Shandil and Venkataraman Balasubramanian and Tanjore Balganesh and Sandeep Tyagi and Jacques Grosset and Giovanna Riccardi and Stewart T Cole},
title = {Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis},
journal = {Science},
year = {2009},
volume = {324},
publisher = {American Association for the Advancement of Science (AAAS)},
month = {may},
url = {https://doi.org/10.1126%2Fscience.1171583},
number = {5928},
pages = {801--804},
doi = {10.1126/science.1171583}
}
MLA
Cite this
MLA Copy
Makarov, Vadim, et al. “Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis.” Science, vol. 324, no. 5928, May. 2009, pp. 801-804. https://doi.org/10.1126%2Fscience.1171583.
Found error?